Agnès Veyradier

5.0k total citations · 1 hit paper
70 papers, 2.1k citations indexed

About

Agnès Veyradier is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Agnès Veyradier has authored 70 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 52 papers in Immunology and 25 papers in Genetics. Recurrent topics in Agnès Veyradier's work include Complement system in diseases (52 papers), Platelet Disorders and Treatments (37 papers) and Renal Diseases and Glomerulopathies (22 papers). Agnès Veyradier is often cited by papers focused on Complement system in diseases (52 papers), Platelet Disorders and Treatments (37 papers) and Renal Diseases and Glomerulopathies (22 papers). Agnès Veyradier collaborates with scholars based in France, Belgium and Morocco. Agnès Veyradier's co-authors include Paul Coppo, Bérangère S. Joly, Dominique Meyer, E Fressinaud, John‐Paul Westwood, Ravi Sarode, Kenneth D. Friedman, Bernadette Obert, Javier de la Rubia and Johanna A. Kremer Hovinga and has published in prestigious journals such as Blood, Gastroenterology and PLoS ONE.

In The Last Decade

Agnès Veyradier

56 papers receiving 2.1k citations

Hit Papers

Thrombotic thrombocytopenic purpura 2017 2026 2020 2023 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Thrombotic thrombocytopenic purpura
    2017 414 citations Bérangère S. Joly, Paul Coppo et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Agnès Veyradier France 23 1.5k 1.2k 741 573 224 70 2.1k
Sylvia Benjamin United Kingdom 14 1.2k 0.8× 766 0.7× 686 0.9× 421 0.7× 105 0.5× 20 1.6k
Joseph H. Troll United States 10 950 0.6× 1.0k 0.9× 414 0.6× 276 0.5× 236 1.1× 11 1.6k
Bérangère S. Joly France 15 797 0.5× 530 0.5× 373 0.5× 323 0.6× 64 0.3× 62 1.1k
Kazuteru Ohashi Japan 27 439 0.3× 1.4k 1.2× 73 0.1× 227 0.4× 139 0.6× 130 2.1k
Görgün Akpek United States 25 385 0.3× 1.1k 0.9× 55 0.1× 399 0.7× 150 0.7× 65 2.0k
Jean‐Claude Davin Netherlands 21 670 0.5× 210 0.2× 889 1.2× 137 0.2× 123 0.5× 35 1.4k
Giovanni Banfi Italy 25 617 0.4× 129 0.1× 1.4k 1.9× 153 0.3× 208 0.9× 46 2.5k
Mathieu Jablonski France 12 726 0.5× 258 0.2× 476 0.6× 104 0.2× 72 0.3× 16 990
P Alessandrino Italy 17 609 0.4× 1.3k 1.1× 53 0.1× 240 0.4× 122 0.5× 25 1.6k
A. Néel France 25 565 0.4× 215 0.2× 112 0.2× 246 0.4× 240 1.1× 100 2.0k

Countries citing papers authored by Agnès Veyradier

Since Specialization
Citations

This map shows the geographic impact of Agnès Veyradier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agnès Veyradier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agnès Veyradier more than expected).

Fields of papers citing papers by Agnès Veyradier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agnès Veyradier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agnès Veyradier. The network helps show where Agnès Veyradier may publish in the future.

Co-authorship network of co-authors of Agnès Veyradier

This figure shows the co-authorship network connecting the top 25 collaborators of Agnès Veyradier. A scholar is included among the top collaborators of Agnès Veyradier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agnès Veyradier. Agnès Veyradier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Joly, Bérangère S., Adrien Joseph, Pierre Boisseau, et al.. (2025). Optimizing ADAMTS13 prophylaxis to reduce relapse and organ failure in congenital thrombotic thrombocytopenic purpura. Blood Advances. 10(5). 1831–1842.
2.
3.
Barbet, Christelle, François Provôt, Pascale Poullin, et al.. (2024). Obinutuzumab in Rituximab Refractory or Intolerant Immune-Mediated Thrombotic Thrombocytopenic Purpura. Blood. 144(Supplement 1). 139–139.
4.
Joly, Bérangère S., et al.. (2022). TTP: From empiricism for an enigmatic disease to targeted molecular therapies. British Journal of Haematology. 197(2). 156–170. 11 indexed citations
5.
Cuker, Adam, Spero R. Cataland, Paul Coppo, et al.. (2021). Redefining outcomes in immune TTP: an international working group consensus report. Blood. 137(14). 1855–1861. 121 indexed citations
6.
Stépanian, Alain, Nadia Anguel, Damien Roux, et al.. (2020). ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease. Research and Practice in Thrombosis and Haemostasis. 5(1). 197–203. 10 indexed citations
7.
Henry, Nicolás, Satar Mortaza, Jean‐François Subra, et al.. (2020). Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab. Frontiers in Medicine. 7. 549931–549931. 3 indexed citations
8.
Gilardin, Laurent, Sandrine Delignat, Ivan Peyron, et al.. (2017). The ADAMTS13 1239–1253 peptide is a dominant HLA-DR1-restricted CD4 + T-cell epitope. Haematologica. 102(11). 1833–1841. 10 indexed citations
9.
Fontbrune, Flore Sicre de, Claire Galambrun, Anne Sîrvent, et al.. (2015). Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Transplantation. 99(9). 1953–1959. 102 indexed citations
10.
11.
12.
Poirault‐Chassac, Sonia, Kim Nguyen, Caterina Casari, et al.. (2013). Terminal Platelet Production is Regulated by Von Willebrand Factor. PLoS ONE. 8(5). e63810–e63810. 19 indexed citations
13.
Mariotte, Éric, Alice Blet, Lionel Galicier, et al.. (2013). Unresponsive thrombotic thrombocytopenic purpura in critically ill adults. Intensive Care Medicine. 39(7). 1272–1281. 24 indexed citations
14.
Veyradier, Agnès & Paul Coppo. (2011). ADAMTS13, la protéase spécifique du clivage du facteur von Willebrand. médecine/sciences. 27(12). 1097–1105. 2 indexed citations
15.
Veyradier, Agnès, Claudine Caron, Catherine Ternisien, et al.. (2011). Validation of the first commercial ELISA for type 2N von Willebrand’s disease diagnosis. Haemophilia. 17(6). 944–951. 16 indexed citations
16.
Veyradier, Agnès, et al.. (2011). Purpura thrombotique thrombocytopénique secondaire à l’utilisation du clopidogrel. La Revue de Médecine Interne. 32(12). 762–765. 5 indexed citations
17.
Rayes, Julie, Paulette Legendre, Agnès Veyradier, et al.. (2007). Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS‐13. Journal of Thrombosis and Haemostasis. 5(2). 321–328. 38 indexed citations
18.
Veyradier, Agnès, Chantal Loirat, Jean‐Pierre Girma, et al.. (2005). Purpura thrombotique thrombocytopénique par déficit héréditaire en ADAMTS13 (syndrome d’Upshaw-Schulman) : actualités et perspectives. Hématologie. 11(5). 321–334. 3 indexed citations
19.
20.
Veyradier, Agnès, E Fressinaud, & Dominique Meyer. (1998). Laboratory diagnosis of von Willebrand disease. International Journal of Clinical & Laboratory Research. 28(4). 201–210. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvia Benjamin Breakdown of academic impact, for papers by Joseph H. Troll Breakdown of academic impact, for papers by Bérangère S. Joly Breakdown of academic impact, for papers by Kazuteru Ohashi Breakdown of academic impact, for papers by Görgün Akpek Breakdown of academic impact, for papers by Jean‐Claude Davin Breakdown of academic impact, for papers by Giovanni Banfi Breakdown of academic impact, for papers by Mathieu Jablonski Breakdown of academic impact, for papers by P Alessandrino Breakdown of academic impact, for papers by A. Néel
Rankless by CCL
2026